miscarriage%20-%20spontaneous
MISCARRIAGE - SPONTANEOUS

Spontaneous miscarriage is the loss of fetus before 20 weeks of gestation or delivery of a fetus weighing <500 g, in the absence of elective medical or surgical measures to terminate pregnancy.
Early loss is considered if it occurred before menstrual week 12 while late loss refers to those that occurred from menstrual week 12-20.
It is also known as spontaneous abortion, spontaneous pregnancy loss or early pregnancy failure.

Drug Information

Dosage: Dysmenorrhoea 10 mg bd from day 5-25 of the cycle. Endometriosis 10 mg bd-tds from day 5-25 of the cycle or co

Indication: Agammaglobulinemia/hypogammaglobulinemia. Combined therapy w/ antibiotics in severe bacterial or viral infecti...

Dosage:  Hormone replacement therapy for women w/ disorders due to natural or surgically induced menopause w/ intact u

Indication: Obstet Induce parturition in cases of uterine inertia during the 3rd stage of labour. Prophylactically & t...

Indication: Antepartum: Induction of labour, augmentation of labour in selected cases of uterine interia. Postpartum: Caes...

Indication: Disorders associated w/ progesterone deficiency eg, infertility due to inadequate luteal phase; for use during...

Indication: Premenstrual syndrome (PMS) including premenstrual tension & depression. Luteal phase support as part of a...

Indication: Replacement therapy in primary immunodeficiency syndromes eg, congenital agammaglobulinaemia & hypogammagl...

Indication: Primary humoral immunodeficiency. Idiopathic thrombocytopenic purpura. Chronic inflammatory demyelinating poly...

Indication: Replacement therapy in primary immunodeficiency syndromes eg, congenital agammaglobulinaemia & hypogammagl...

1  /  3
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 20 May 2020

The combination of olaparib and bevacizumab as maintenance therapy for advanced ovarian cancer appears to confer the greatest progression-free survival (PFS) benefit in women without residual macroscopic disease following upfront cytoreductive surgery, according to an analysis of the phase III PAOLA-1* trial.